December 21, 2016 10:58 AM EST

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout

John Carroll

Editor & Founder

Japan’s Sumitomo Dainippon Pharma has stepped up with a $200 million down payment on its purchase of Salt Lake City-based Tolero Pharmaceuticals. There’s another …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout

John Carroll

Editor & Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Sum­it­o­mo Dainip­pon beefs up on­col­o­gy pipeline with $780M Tolero buy­out

Editor & Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout